Dr. Reddy’s Announces The Launch Of Atorvastatin Calcium Tablets

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched ATORVASTATIN CALCIUM TABLETS 10 mg, 20 mg, 40 mg and 80 mg, a bioequivalent generic version of LIPITOR ® (atorvastatin calcium) tablets, in the US market on July 17, 2012 following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy’s ANDA for atorvastatin calcium tablets.

The LIPITOR ® brand had U.S. sales of approximately $8.07 billion for the most recent twelve months ending March 2012 according to IMS Health.

Dr. Reddy’s Atorvastatin Calcium Tablets in 10 mg, 20 mg, 40 mg and 80 mg are available in bottle count sizes of 90 and 500.

Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to: www.drreddys.com

LIPITOR ® is a registered trademark of Pfizer Inc.

IMS National Sales Perspectives: Retail and Non-Retail MAT March 2012

Copyright Business Wire 2010